HIGHLIGHTS
- who: Pujitha Vallivedu Chennakesavulu and colleagues from the College, Vijayawada, IND have published the article: Review began 02/01/2022 Review ended 08/15/2022 Published 08/16/2022 u00a9 Copyright, in the Journal: (JOURNAL) of August/16,/2022
- what: The authors also report the established efficacy in determining over various comorbidities and adverse effects of vaccines. The review article proposes that the vaccines in these phase III clinical trials have good neutralizing antibodies against the SARS-CoV-2, thus decreasing the incidence.
- how: A Phase-II data indicated that seroconversion of neutralizing . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.